Injective (INJ) is currently priced at $3.65, reflecting a 5.45% increase over the last 24 hours, indicating positive short-term momentum. The daily price range has been tight, fluctuating between $3.46 and $3.65, showcasing stability in the current market.

The trading volume stands at approximately 51.73 million, translating to a 14.17% ratio of volume to market cap, suggesting a healthy level of trading activity. Notably, the hourly moving averages demonstrate a bullish trend with the 55 SMA showing a notable gain of 5.53%, indicating short-term upward momentum.

The 1-hour RSI is at 56, suggesting that the asset is neither overbought nor oversold, allowing for further upward movement. In the longer-term view, the 7-day RSI at 57 and a significant 13.77% increase over the past week indicate sustained buying interest.

Over the past 14 days, INJ has appreciated by 24.89%, while the 30-day price change stands at 23.07%, highlighting strong bullish momentum. Despite the current price being significantly below its all-time high of $52.62 achieved earlier this year, the upward trajectory indicates a potential recovery path.

Given the current technical indicators, including the positive price action, healthy RSI readings, and strong moving averages, the outlook for Injective appears favorable. Therefore, I recommend a Buy rating for INJ, as the market shows signs of continued upward momentum with the potential for further gains in the near term.